Reversal of Immunogenicity in Pediatric Inflammatory Bowel Disease Patients Receiving Anti-Tumor Necrosis Factor Medications

Loss of response to anti-tumor necrosis factor (anti-TNF) agents in the treatment of inflammatory bowel disease (IBD) is a major consideration to maintain sustained response. Reversal of immunogenicity can re-establish response and increase the durability of these agents. Strategies to reverse immun...

Descripción completa

Detalles Bibliográficos
Autores principales: Kang, Elise, Khalili, Ali, Splawski, Judy, Sferra, Thomas J., Moses, Jonathan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Society of Pediatric Gastroenterology, Hepatology and Nutrition 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6182480/
https://www.ncbi.nlm.nih.gov/pubmed/30345247
http://dx.doi.org/10.5223/pghn.2018.21.4.329

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6182480/
https://www.ncbi.nlm.nih.gov/pubmed/30345247
http://dx.doi.org/10.5223/pghn.2018.21.4.329

Ejemplares similares